-
公开(公告)号：US08614064B2
公开(公告)日：2013-12-24
申请号：US10557283
申请日：2004-05-24
Applicant: Subroto Chatterjee , Peter O. Kwiterovich
Inventor： Subroto Chatterjee , Peter O. Kwiterovich
IPC: G01N33/53 , C07K14/775
CPC classification number: G01N33/92 , G01N33/6893 , G01N2500/00 , G01N2500/04 , G01N2800/323 , G01N2800/324
Abstract: The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.
Abstract translation: 本发明提供用于鉴定抑制ApoCI并可用于治疗或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的化合物的方法和组合物。 本发明还提供了治疗患有或具有发展动脉粥样硬化，斑块破裂，凋亡或心肌梗塞的风险的受试者的方法。 本发明还提供了用于诊断患有或处于或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的受试者的方法。
-
12.发明申请PECAM-1-related molecules compositions kit of parts and associated methods of use 审中-公开PECAM-1相关分子组成成分试剂盒及相关使用方法公开(公告)号：US20060127921A1
公开(公告)日：2006-06-15
申请号：US11158447
申请日：2005-06-21
Applicant: Subroto Chatterjee , Heming Wei
Inventor： Subroto Chatterjee , Heming Wei
CPC classification number: A61K38/17 , C07K14/70503 , C07K16/2803 , C12N5/0645 , C12N2501/58
Abstract: An isolated polynucleotide coding for platelet endothelial cell adhesion molecule-1 (PECAM-1), and obtainable by amplifying cDNA from total human white blood cells by PCR; peptides encoding PECAM-1 5th Ig-like domain; an antibody against one of the peptides; associated compositions methods and kits of parts.
Abstract translation: 编码血小板内皮细胞粘附分子-1（PECAM-1）的分离的多核苷酸，可通过PCR从总人白细胞中扩增cDNA获得; 编码PECAM-15第3型Ig样结构域的肽; 针对一种肽的抗体; 相关组合方法和零件套件。
-
公开(公告)号：US06713057B1
公开(公告)日：2004-03-30
申请号：US09511532
申请日：2000-02-23
Applicant: Subroto Chatterjee
Inventor： Subroto Chatterjee
IPC: A61K3846
CPC classification number: G01N33/92 , A61K31/164 , A61K38/1709 , G01N2800/044 , A61K2300/00
Abstract: Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.
Abstract translation: 提供了用于调节受试哺乳动物血清胆固醇的组合物和方法。 一方面，本发明的特征在于新型抗血脂药物，其包括至少一种鉴定的低密度脂蛋白（LDL）受体的效应物和至少一种鉴定的血清胆固醇抑制剂。 在一个特定方面，所述药物包括与所鉴定的一种血清胆固醇抑制剂相连的一种鉴别的鞘脂或蛋白质修饰。 另外提供了用于鉴定能够调节LDL受体和特异性SREBP-1成熟的抗血脂药物的方法，包括设计用于鉴定能够稳定或降低哺乳动物，特别是人类患者血清胆固醇水平的药理学药物的测定法。
-
公开(公告)号：US06511979B1
公开(公告)日：2003-01-28
申请号：US09359023
申请日：1999-07-22
Applicant: Subroto Chatterjee
Inventor： Subroto Chatterjee
IPC: A61K31535
CPC classification number: A61K38/1858 , A61K31/00 , A61K31/16 , A61K31/40 , A61K31/4453 , A61K31/5375 , A61K38/1709 , A61K38/191 , A61K2300/00
Abstract: The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDPGal:GlcCer&bgr;1→4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.
Abstract translation: 本发明包括用于治疗和预防与乳糖神经酰胺相关的病症的方法。 所述方法通常提供给哺乳动物，特别是人类施用治疗有效量的增加UDPGal：GlcCerbeta1-4半乳糖神经酰胺（GalT-2）的酶活性的化合物。 还提供了用于检测具有调节GalT-2的治疗能力的化合物的体外和体内测定。
-
公开(公告)号：US08492351B2
公开(公告)日：2013-07-23
申请号：US12488965
申请日：2009-06-22
Applicant: Subroto Chatterjee , Mark S. Butler , Brinda Somanadhan
Inventor： Subroto Chatterjee , Mark S. Butler , Brinda Somanadhan
CPC classification number: A61K31/192 , A23L33/105 , A23V2002/00 , A61K31/235 , A61K31/365 , A61K31/366 , A61K31/7024 , A61K31/7034 , A61K31/7048 , A61K36/53 , A61K36/81 , A61K45/06 , A61K47/481 , A61K47/55 , C07C69/84 , C07H13/08 , A23V2250/21 , A23V2200/3262
Abstract: The present invention provides novel compounds with hypocholesteremic activity from crude Embilica officinialis (EO) extracts and methods of use. The invention also provides nutraceuticals.
Abstract translation: 本发明提供了由粗提取物（EO）提取物和使用方法提供具有低胆固醇活性的新型化合物。 本发明还提供营养品。
-
Patent Agency Ranking
16.发明申请Use of the Lactosylceramide Synthase Isoform B1,4GALT-V as a Biomarker for Cancer 有权使用乳糖神经酰胺合酶异构体B1,4GALT-V作为癌症的生物标志物公开(公告)号：US20130041015A1
公开(公告)日：2013-02-14
申请号：US13578657
申请日：2010-02-12
Applicant: Subroto Chatterjee
Inventor： Subroto Chatterjee
IPC: A61K31/713 , A61P35/00 , A61K31/5375 , G01N33/574 , C40B30/04
CPC classification number: G01N33/57484 , C12Q1/48 , G01N33/57419 , G01N33/57438 , G01N2800/56
Abstract: In one aspect, B1,4GalT-V, an isoform of the enzyme lactosylceramide synthase, is provided as a biomarker for cancer. Also provided are methods and compositions directed at cancers characterized by the overexpression or upregulation of the lactosylceramide synthase isoform B1,4GalT-V.
Abstract translation: 一方面，作为癌症的生物标志物，提供了作为乳糖基神经酰胺酶合酶的同工型的B1,4GalT-V。 还提供了针对癌症的方法和组合物，其特征在于乳糖神经酰胺合酶异构体B1,4GalT-V的过表达或上调。
-
公开(公告)号：US20100063153A1
公开(公告)日：2010-03-11
申请号：US12488965
申请日：2009-06-22
Applicant: Subroto Chatterjee , Mark S. Butler , Brinda Somanadhan
Inventor： Subroto Chatterjee , Mark S. Butler , Brinda Somanadhan
IPC: A61K31/192 , A61P7/00
CPC classification number: A61K31/192 , A23L33/105 , A23V2002/00 , A61K31/235 , A61K31/365 , A61K31/366 , A61K31/7024 , A61K31/7034 , A61K31/7048 , A61K36/53 , A61K36/81 , A61K45/06 , A61K47/481 , A61K47/55 , C07C69/84 , C07H13/08 , A23V2250/21 , A23V2200/3262
Abstract: The present invention provides novel compounds with hypocholesteremic activity from crude Embilica officinialis (EO) extracts and methods of use. The invention also provides nutraceuticals.
Abstract translation: 本发明提供了由粗提取物（EO）提取物和使用方法提供具有低胆固醇活性的新型化合物。 本发明还提供营养品。
-
公开(公告)号：US20090202439A1
公开(公告)日：2009-08-13
申请号：US11708281
申请日：2007-02-19
Applicant: Subroto Chatterjee
Inventor： Subroto Chatterjee
IPC: A61K39/395 , A61K31/16 , A61K31/5375 , A61K31/445 , A61K31/40 , A61K38/00 , A61K31/7105 , A61K49/00 , A61P35/00 , G01N33/53
CPC classification number: C07K16/2803 , A61K31/16 , A61K38/00 , C07K16/40 , C07K2317/34
Abstract: The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration to a subject one or more compounds that alter the activity of VEGF pathway members, including LacCer synthase (GalT-V/VI), PECAM1, VEGFR, VEGF or related pathway members to treat a subject suffering from or susceptible to a condition caused or contributed to by VEGF. The present invention also relates to methods for detecting and analyzing compounds with therapeutic capacity to treat such condition.
Abstract translation: 本发明包括治疗和预防与乳糖神经酰胺相关的疾病，手术后疾病和细菌感染的方法。 所述方法通常提供给受试者一种或多种改变VEGF途径成员（包括LacCer合酶（GalT-V / VI），PECAM1，VEGFR，VEGF或相关途径成员的活性的化合物），以治疗患有或易感的受试者 由VEGF引起或促成的病症。 本发明还涉及用于检测和分析治疗这种病症的治疗能力的化合物的方法。
-
公开(公告)号：US20070178438A1
公开(公告)日：2007-08-02
申请号：US10557283
申请日：2004-05-24
Applicant: Subroto Chatterjee , Peter Kwiterowich
Inventor： Subroto Chatterjee , Peter Kwiterowich
IPC: C12Q1/00 , C12Q1/68 , G01N33/567
CPC classification number: G01N33/92 , G01N33/6893 , G01N2500/00 , G01N2500/04 , G01N2800/323 , G01N2800/324
Abstract: The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.
Abstract translation: 本发明提供用于鉴定抑制ApoCI并可用于治疗或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的化合物的方法和组合物。 本发明还提供了治疗患有或具有发展动脉粥样硬化，斑块破裂，凋亡或心肌梗塞的风险的受试者的方法。 本发明还提供了用于诊断患有或处于或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的受试者的方法。
-
公开(公告)号：US20050079998A1
公开(公告)日：2005-04-14
申请号：US10640502
申请日：2003-08-13
Applicant: Subroto Chatterjee
Inventor： Subroto Chatterjee
IPC: A61K38/46 , A61K38/57 , G01N33/92 , A61K38/00 , A61K31/366 , A61K31/401 , A61K31/685
CPC classification number: G01N33/92 , A61K31/164 , A61K38/1709 , G01N2800/044 , A61K2300/00
Abstract: Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.
Abstract translation: 提供了用于调节受试哺乳动物血清胆固醇的组合物和方法。 一方面，本发明的特征在于新型抗血脂药物，其包括至少一种鉴定的低密度脂蛋白（LDL）受体的效应物和至少一种鉴定的血清胆固醇抑制剂。 在一个特定方面，所述药物包括与所鉴定的一种血清胆固醇抑制剂相连的一种鉴别的鞘脂或蛋白质修饰。 另外提供了用于鉴定能够调节LDL受体和特异性SREBP-1成熟的抗血脂药物的方法，包括设计用于鉴定能够稳定或降低哺乳动物，特别是人类患者血清胆固醇水平的药理学药物的测定法。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.03 seconds)
